Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Changes In Lymphatic Vessels Can Aid Early Identification of Aggressive Oral Cancer

By LabMedica International staff writers
Posted on 23 Feb 2026

Oral cancers are the most common malignant tumors in the head and neck region and cause more than 188,000 deaths worldwide each year. More...

Unlike many other cancers, even small, early-stage oral tumors can be life-threatening. In Finland, up to one in five patients treated at an early stage later die from the disease. Researchers have now identified a biological marker within tumor lymphatic vessels that may help detect high-risk oral cancers at diagnosis.

In a study conducted by researchers at the University of Turku (Turku, Finland), the team analyzed early-stage oral cancer samples from approximately 300 Finnish patients, focusing on defense and structural cells within tumor tissue. By examining multiple protein markers, the researchers identified an unexpected pattern: certain tumors contained an unusually high number of proliferating lymphatic vessels. In healthy oral tissue, lymphatic vessel cells rarely divide and do not typically express proteins linked to cell division.

Tumors with a higher number of proliferating lymphatic vessels were strongly associated with cancer recurrence and mortality. The presence of these dividing lymphatic vessel cells predicted disease progression more accurately than previously established risk factors for oral cancer. The findings, published in Cell Reports Medicine, suggest that assessing these protein markers in lymphatic vessel surface cells could help identify aggressive forms of oral cancer at an early stage.

Early identification of high-risk tumors may allow clinicians to tailor treatment strategies more precisely. Currently, oral cancer treatment primarily involves surgery, and there are limited tools for guiding adjuvant therapy decisions. Researchers believe the newly identified marker could serve as a practical clinical tool and are interested in exploring whether it has similar predictive value in other cancer types.

“We are excited about the results and believe that the findings could also be applied as a practical tool for clinical use,” said the lead author of the study Joni Näsiaho. “Furthermore, it would be interesting to find out whether the marker we discovered has a similar predictive value in other cancer groups.”

Related Links:
University of Turku


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Automated Immunoassay Analyzer
SuperFlex™
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.